SequelSEC

NeuroPace Inc NPCE

Surgical & Medical Instruments & Apparatus · CIK 0001528287 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$22.83M
Fiscal year ended 2026-06-30
Operating income
-$5.14M
Fiscal year ended 2026-06-30
Free cash flow
-$4.03M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$306.20MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$9.09Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue3.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity16.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.3%5th
Long-term debt / equity3.09x94th
Gross margin77.2%85th
Current ratio5.28x77th
Revenue YoY growth25.1%71th
R&D / revenue27.9%63th
SBC / revenue11.1%61th
Operating margin-16.3%53th
FCF margin-11.3%51th
Net margin-21.5%51th

NeuroPace Inc (NPCE) reported revenue of $22.83M and net income of -$6.20M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NeuroPace Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NeuroPace Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$22.83M$22.07M$26.59M$27.35M$19.50M$22.52M$21.47M$21.06M$19.26M$18.12M
Cost of revenue$3.92M$4.02M$6.01M$6.19M$3.29M$5.18M$5.28M$5.64M$5.12M$4.78M
Gross profit$18.91M$18.05M$20.58M$21.17M$16.21M$17.34M$16.19M$15.42M$14.13M$13.34M
Operating income-$5.14M-$5.57M-$1.77M-$2.60M-$8.19M-$5.15M-$3.65M-$4.24M-$6.23M-$7.54M
Net income-$6.20M-$6.69M-$2.73M-$3.50M-$8.65M-$6.59M-$5.25M-$5.45M-$7.51M-$8.92M
Research & development$6.90M$7.19M$7.03M$6.58M$6.84M$7.44M$6.05M$5.75M$6.06M$5.78M
Weighted-average diluted sharesshares 34.10Mshares 33.72MUnavailableshares 33.13Mshares 32.86Mshares 31.48MUnavailableshares 29.44Mshares 28.85Mshares 28.29M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailable$0$0$0$0$0Unavailable$0$0$0
Diluted EPS$-0.18$-0.20Unavailable$-0.11$-0.26$-0.21Unavailable$-0.19$-0.26$-0.32
Selling, general & administrative$17.15M$16.43M$15.32M$17.19M$17.56M$15.05M$13.79M$13.91M$14.30M$15.10M
General & administrative$5.03M$4.84M$4.38M$4.59M$6.07M$4.05M$3.84M$3.98M$4.54MUnavailable
Selling & marketing$12.12M$11.58M$10.94M$12.60M$11.49M$11.00M$9.95M$9.93M$9.76MUnavailable

Balance

NeuroPace Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$12.54M$14.78M$21.69M$20.65M$22.86M$27.02M$13.43M$15.42M$12.84M$13.00M
Total assets$96.99M$98.90M$105.56M$107.26M$106.11M$110.20M$94.65M$96.30M$94.39M$98.85M
Current assets$86.19M$86.98M$94.07M$95.33M$93.74M$97.48M$81.34M$82.59M$80.23M$84.25M
Total liabilities$85.11M$84.44M$86.53M$88.74M$86.68M$85.94M$86.63M$86.48M$84.50M$84.51M
Current liabilities$17.43M$16.17M$17.81M$19.61M$17.14M$14.71M$15.16M$14.78M$12.58M$13.11M
Total equity incl. NCI$11.88M$14.45M$19.03M$18.52M$19.44M$24.27M$8.01M$9.82M$9.88M$14.34M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$18.11M$16.69M$14.86M$18.14M$16.35M$13.58M$13.38M$12.08M$11.36M$11.42M
Accounts receivable$14.93M$14.79M$12.94M$14.94M$13.55M$15.44M$12.85M$11.56M$11.24M$11.63M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$59.01M$59.02M$58.88M$58.75M$58.62M$59.79M$59.52M$59.27M$59.02M$58.04M
Accounts payable$4.20M$4.51M$1.78M$4.59M$4.72M$4.05M$2.95M$2.16M$2.29M$3.27M

Cash flow

NeuroPace Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$3.90M-$5.90M$506.00K-$1.94M-$2.09M-$7.48M-$4.80M-$1.72M-$3.90M-$7.53M
Capital expenditures$125.00K$117.00K$97.00K$30.00K$168.00K$37.00K$39.00K$100.00K$63.00K$104.00K
Investing cash flow-$125.00K-$117.00K-$97.00K-$30.00K-$168.00K-$37.00K$1.96M$1.40M$3.24M$2.40M
Financing cash flow$1.18M-$166.00K$635.00K-$235.00K-$1.91M$21.11M$848.00K$2.90M$509.00K$72.00K
Net change in cash-$2.85M-$6.18M$1.04M-$2.21M-$4.16M$13.59M-$1.99M$2.57M-$154.00K-$5.06M
Stock-based compensation$2.30M$2.28M$2.61M$2.63M$3.23M$2.63M$2.60M$2.59M$2.55M$2.54M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$0$0$0$0$49.55M$0$0$0$0
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

NeuroPace Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$4.03M-$6.02M$409.00K-$1.97M-$2.25M-$7.52M-$4.84M-$1.82M-$3.96M-$7.63M
Gross margin82.8%81.8%77.4%77.4%83.1%77.0%75.4%73.2%73.4%73.6%
Operating margin-22.5%-25.2%-6.6%-9.5%-42.0%-22.9%-17.0%-20.1%-32.4%-41.6%
FCF margin-17.6%-27.3%1.5%-7.2%-11.6%-33.4%-22.5%-8.7%-20.6%-42.1%
SBC / revenue10.1%10.3%9.8%9.6%16.6%11.7%12.1%12.3%13.2%14.0%
Current ratio4.94x5.38x5.28x4.86x5.47x6.63x5.37x5.59x6.37x6.43x
Revenue YoY growth17.1%-2.0%23.9%29.9%1.3%24.3%19.2%28.2%16.6%25.2%
Net margin-27.2%Unavailable-10.3%-12.8%-44.4%Unavailable-24.5%-25.9%UnavailableUnavailable
R&D / revenue30.2%32.6%26.4%24.0%35.1%33.0%28.2%27.3%31.5%31.9%
CapEx / revenue0.5%0.5%0.4%0.1%0.9%0.2%0.2%0.5%0.3%0.6%
Long-term debt / equity4.97xUnavailable3.09x3.17xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NPCE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.